» Articles » PMID: 34960969

Reactive Oxygen Species-Responsive Miktoarm Amphiphile for Triggered Intracellular Release of Anti-Cancer Therapeutics

Overview
Publisher MDPI
Date 2021 Dec 28
PMID 34960969
Authors
Affiliations
Soon will be listed here.
Abstract

Reactive oxygen species (ROS)-responsive nanocarriers have received considerable research attention as putative cancer treatments because their tumor cell targets have high ROS levels. Here, we synthesized a miktoarm amphiphile of dithioketal-linked ditocopheryl polyethylene glycol (DTTP) by introducing ROS-cleavable thioketal groups as linkers between the hydrophilic and hydrophobic moieties. We used the product as a carrier for the controlled release of doxorubicin (DOX). DTTP has a critical micelle concentration (CMC) as low as 1.55 μg/mL (4.18 × 10 mM), encapsulation efficiency as high as 43.6 ± 0.23% and 14.6 nm particle size. The DTTP micelles were very responsive to ROS and released their DOX loads in a controlled manner. The tocopheryl derivates linked to DTTP generated ROS and added to the intracellular ROS in MCF-7 cancer cells but not in HEK-293 normal cells. In vitro cytotoxicity assays demonstrated that DOX-encapsulated DTTP micelles displayed strong antitumor activity but only slightly increased apoptosis in normal cells. This ROS-triggered, self-accelerating drug release device has high therapeutic efficacy and could be a practical new strategy for the clinical application of ROS-responsive drug delivery systems.

References
1.
Wang X, Dong L, Zhao Y, Tomasetti M, Wu K, Neuzil J . Vitamin E analogues as anticancer agents: lessons from studies with alpha-tocopheryl succinate. Mol Nutr Food Res. 2006; 50(8):675-85. DOI: 10.1002/mnfr.200500267. View

2.
Lotocki V, Kakkar A . Miktoarm Star Polymers: Branched Architectures in Drug Delivery. Pharmaceutics. 2020; 12(9). PMC: 7559275. DOI: 10.3390/pharmaceutics12090827. View

3.
Trachootham D, Alexandre J, Huang P . Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov. 2009; 8(7):579-91. DOI: 10.1038/nrd2803. View

4.
Lv X, Zhu Y, Ghandehari H, Yu A, Wang Y . An ROS-responsive and self-accelerating drug release nanoplatform for overcoming multidrug resistance. Chem Commun (Camb). 2019; 55(23):3383-3386. DOI: 10.1039/c9cc00358d. View

5.
Vonarbourg A, Passirani C, Saulnier P, Benoit J . Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials. 2006; 27(24):4356-73. DOI: 10.1016/j.biomaterials.2006.03.039. View